Combined targeting of CCL7 and Flt3L to promote the expansion and infiltration of cDC1s in tumors enhances T-cell activation and anti-PD-1 therapy effectiveness in NSCLC.
作者信息
Dong Hong-Peng, Li Ying, Tang Zhen, Wang Peng, Zhong Bo, Chu Qian, Lin Dandan
机构信息
Cancer Center, Renmin Hospital of Wuhan University, Medical Research Institute and Frontier Science Center of Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.
College of Life Sciences, Wuhan University, Wuhan, 430072, China.
出版信息
Cell Mol Immunol. 2023 Jul;20(7):850-853. doi: 10.1038/s41423-023-00991-5. Epub 2023 Mar 9.
Abstract
摘要
相似文献
1
Combined targeting of CCL7 and Flt3L to promote the expansion and infiltration of cDC1s in tumors enhances T-cell activation and anti-PD-1 therapy effectiveness in NSCLC.联合靶向CCL7和Flt3L以促进肿瘤中cDC1的扩增和浸润，可增强非小细胞肺癌中T细胞的活化及抗PD-1治疗效果。
Cell Mol Immunol. 2023 Jul;20(7):850-853. doi: 10.1038/s41423-023-00991-5. Epub 2023 Mar 9.
2
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.CCL7 招募 cDC1 以促进抗肿瘤免疫并促进非小细胞肺癌的检查点免疫治疗。
Nat Commun. 2020 Nov 30;11(1):6119. doi: 10.1038/s41467-020-19973-6.
3
Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.在非小细胞肺癌模型中，肿瘤治疗电场通过诱导免疫原性细胞死亡来提高CCL2/8和CXCL9/CXCL10的表达，从而增强抗PD治疗效果。
BMC Cancer. 2025 Mar 17;25(1):489. doi: 10.1186/s12885-025-13859-w.
4
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137T-cells.IgM 型类风湿因子通过减少 CD137T 细胞赋予 NSCLC 患者对 PD-1 免疫治疗的原发性耐药性。
EBioMedicine. 2020 Dec;62:103098. doi: 10.1016/j.ebiom.2020.103098. Epub 2020 Nov 6.
5
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy.抗 PD-1 抗体介导的 17 型 T 细胞的激活会破坏检查点阻断疗法。
Cancer Immunol Immunother. 2021 Jun;70(6):1789-1796. doi: 10.1007/s00262-020-02795-2. Epub 2020 Nov 27.
6
A novel anti-PD-L1 DNA aptamer, Apta35 enhances non-small cell lung cancer cell cytotoxicity and apoptosis through lung cancer-activated T lymphocytes.一种新型抗PD-L1 DNA适配体Apta35通过肺癌激活的T淋巴细胞增强非小细胞肺癌细胞的细胞毒性和凋亡。
Int Immunopharmacol. 2025 May 16;155:114621. doi: 10.1016/j.intimp.2025.114621. Epub 2025 Apr 10.
7
EGFR mutations induce the suppression of CD8 T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.表皮生长因子受体突变通过 ERK1/2-p90RSK-TGF-β 轴诱导非小细胞肺癌中 CD8 T 细胞的抑制和抗 PD-1 耐药。
J Transl Med. 2024 Jul 14;22(1):653. doi: 10.1186/s12967-024-05456-5.
8
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.外周血中性粒细胞与淋巴细胞比值（dNLR）较低与非小细胞肺癌一线帕博利珠单抗治疗时肿瘤 T 细胞浸润增加和预后改善相关。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003536.
9
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.T 淋巴细胞的独特耗竭特征塑造了肿瘤免疫微环境，这对非小细胞肺癌患者具有治疗意义。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-002780.
10
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.抗 PD-1 治疗后非小细胞肺癌和肾细胞癌患者免疫细胞群和可溶性介质的外周变化。
Cancer Immunol Immunother. 2019 Oct;68(10):1585-1596. doi: 10.1007/s00262-019-02391-z. Epub 2019 Sep 12.
引用本文的文献
1
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation.肿瘤微环境驱动的非小细胞肺癌免疫治疗耐药性：冷肿瘤向热肿瘤转变的策略
Cancer Drug Resist. 2025 Apr 24;8:21. doi: 10.20517/cdr.2025.14. eCollection 2025.
2
Function of antigen-presenting cells in non-small-cell lung cancer (NSCLC).抗原呈递细胞在非小细胞肺癌（NSCLC）中的作用。
Med Oncol. 2025 Apr 12;42(5):162. doi: 10.1007/s12032-025-02703-7.
3
Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers.逆向工程FLT3-PI3K/AKT轴以增强肿瘤浸润淋巴细胞功能并改善卵巢癌和宫颈癌的预后。
J Ovarian Res. 2025 Jan 25;18(1):14. doi: 10.1186/s13048-025-01592-8.
4
TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma.TAK1 通过胰腺癌相关成纤维细胞表型转化促进免疫抑制性肿瘤微环境。
Clin Cancer Res. 2024 Nov 15;30(22):5138-5153. doi: 10.1158/1078-0432.CCR-24-1004.
5
Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.肿瘤微环境中的趋化因子：对肺癌和免疫治疗的影响
Front Immunol. 2024 Jul 16;15:1443366. doi: 10.3389/fimmu.2024.1443366. eCollection 2024.
本文引用的文献
1
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.免疫检查点阻断的反应、耐药和毒性的特征。
Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 7.
2
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.针对肿瘤反应性 T 细胞的 IL-21 可增强记忆 T 细胞应答和抗 PD-1 抗体治疗。
Nat Commun. 2021 Feb 11;12(1):951. doi: 10.1038/s41467-021-21241-0.
3
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.CCL7 招募 cDC1 以促进抗肿瘤免疫并促进非小细胞肺癌的检查点免疫治疗。
Nat Commun. 2020 Nov 30;11(1):6119. doi: 10.1038/s41467-020-19973-6.
4
Tumor-infiltrating lymphocytes in the immunotherapy era.免疫治疗时代的肿瘤浸润淋巴细胞。
Cell Mol Immunol. 2021 Apr;18(4):842-859. doi: 10.1038/s41423-020-00565-9. Epub 2020 Nov 2.
5
cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity.cDC1 呈递抗原并被 CD4 T 细胞许可，以诱导抗肿瘤免疫。
Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12.
6
Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.- 突变与 PD-1 抑制剂耐药在 - 突变型肺腺癌中的研究进展
Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
7
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.肿瘤部位CD103(+)树突状细胞祖细胞的扩增与激活增强了肿瘤对治疗性PD-L1和BRAF抑制的反应。
Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.
8
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.同时发生的基因组改变定义了具有不同生物学特性、免疫特征和治疗易感性的KRAS突变型肺腺癌的主要亚组。
Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.
9
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.重组人Flt3L（CDX-301）在健康人类志愿者中扩增树突状细胞和造血干细胞的有效性及安全性。
Bone Marrow Transplant. 2015 Jul;50(7):924-30. doi: 10.1038/bmt.2015.74. Epub 2015 Apr 27.
10
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice.CCR2 红色荧光蛋白基因敲入小鼠中枢神经系统髓系细胞趋化因子受体的选择性使用。
PLoS One. 2010 Oct 27;5(10):e13693. doi: 10.1371/journal.pone.0013693.
Zotero 插件